SENOGUARD, INC.

Medtech · Private

Minimally invasive cryoablation probe and external cryoagent controller for post-lumpectomy thermal therapy

Grants
$1.3M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Cryogenic probe development and testing for post-lumpectomy margin ablation treatment$255,731
Federal grantNational Science Foundation · Phase II · SBIR Phase II: Cryogenic probe development and testing for post-lumpectomy margin ablation treatment$999,545
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1121HOSPI CORPORATION—$7.0M
1122Oralucent, Inc.—$2.3M
1123TEAL HEALTH INC—$45M
1124SENOGUARD, INC.——
1125NX Prenatal Inc.—$5.8M
1126iNanoBio, Inc.—$3.3M
1127ZeoVation, Inc.—$780K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 5
  • Apparatus And Method For Marginal Ablation In Tissue Cavityapplication
  • Apparatus And Method For Ablation Of Soft Tissue Surrounding A Breast Cavity Following Lumpectomyapplication
  • Apparatus And Method For Marginal Ablation In Tissue Cavityapplication
  • Apparatus And Method For Ablation Of Soft Tissue Surrounding A Breast Cavity Following Lumpectomy Using A Fixed Probeapplication
  • Apparatus And Method For Ablation Of Soft Tissue Surrounding A Breast Cavity Following Lumpectomyapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.